Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Peacock, G. Burgess, T. Parpia, R. Barst (Glasgow, Sandwich, United Kingdom; New York, United States Of America). Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients. Eur Respir J 2005; 26: Suppl. 49, 3127

Member's Comments

No comment yet.

Related content which might interest you: Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Haemodynamics during vasodilator test comparing urapidil and nicardipine to NO in pulmonary arterial hypertension Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH) Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Long-term effects of bosentan on the heart and pulmonary hemodynamics in pulmonary arterial hypertension, a comparison study with epoprostenol Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1 Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Pulmonary haemodynamics during exercise in patients with pulmonary arterial hypertension Source: Annual Congress 2005 - Exercise testing in pulmonary arterial hypertension Year: 2005 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 92-98 Year: 2009 Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 393-398 Year: 2008 Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy Source: Eur Respir J 2005; 26: Suppl. 49, 476s Year: 2005 Clinical, functional and hemodynamic response after six months of sildenafil in patients with pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary circulation Year: 2007